A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples